Los Angeles Capital Management LLC Boosts Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Los Angeles Capital Management LLC grew its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 2,625.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,700 shares of the biotechnology company’s stock after purchasing an additional 319,528 shares during the period. Los Angeles Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $1,469,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in IRWD. Pacer Advisors Inc. increased its position in shares of Ironwood Pharmaceuticals by 26.6% in the third quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 2,372,183 shares during the last quarter. Stonepine Capital Management LLC grew its stake in Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after buying an additional 951,988 shares in the last quarter. State Street Corp increased its holdings in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 23.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after buying an additional 364,841 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its position in shares of Ironwood Pharmaceuticals by 1,293.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company’s stock valued at $1,570,000 after buying an additional 353,624 shares in the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on IRWD shares. JMP Securities cut their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. Craig Hallum cut their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Finally, StockNews.com lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Stock Down 0.6 %

Ironwood Pharmaceuticals stock opened at $1.61 on Friday. The firm has a fifty day simple moving average of $3.16 and a two-hundred day simple moving average of $3.84. Ironwood Pharmaceuticals, Inc. has a twelve month low of $1.55 and a twelve month high of $11.00. The company has a market capitalization of $257.65 million, a PE ratio of -53.67 and a beta of 0.29.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). The company had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. As a group, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.